We are pleased to announce that Professor Fernando Albericio has joined JYMed Peptide as Chief Scientific Advisor.It is a privilege to welcome him to the team. Internationally recognized for his extensive contributions to peptide chemistry, including solid-phase...
Our Blog
Happy Labor Day!
Behind every peptide project, there are people making the work possible.From research and production to quality, operations, and customer support, Labor Day is the perfect time to recognize the teams whose dedication makes everything possible, every day.Happy Labor...
JYMed Peptide Secures FDA Completeness Assessment for Second Semaglutide DMF
JYMed Peptide’s New Semaglutide DMF No. 041090 Listed as “Available for Reference” by the U.S. FDA JYMed Peptide recently announced that an additional Drug Master File (DMF) for its Semaglutide active pharmaceutical ingredient (API), DMF No. 041090, has successfully...
Hubei JXBio Receives NMPA Approval for Icatibant Acetate API
Recently, Hubei JXBio Pharmaceutical Co., Ltd. ("Hubei JXBio"), the peptide manufacturing base of Jianyuan Pharmaceuticals, received the Chemical API Marketing Approval Notification for Icatibant Acetate (Registration No.: Y20240000910) issued by the...
Announcement | JYMed Peptide Appoints Dr. ZhaoBo Gao as Chief Operating Officer (COO)
To Our Valued Clients, Partners, and Friends, We are pleased to announce the appointment of Dr. ZhaoBo Gao as Chief Operating Officer (COO) of JYMed Peptide. Dr. Gao brings more than 20 years of successful experience in...
March 2026: Key News in GLP-1 & Peptide Drugs
Date: March 2026 | 1. FDA Crackdown on Unapproved Compounded GLP-1 Products The U.S. FDA issued 30 warning letters to telehealth companies and compounding pharmacies marketing unapproved compounded GLP-1 products (e.g., semaglutide, tirzepatide) with false efficacy...
JYMed Peptide Receives FDA DMF Acknowledgment for Semaglutide API Manufactured Under a New Process
JYMed is pleased to announce that the U.S. Food and Drug Administration has acknowledged receipt of a new Type II Drug Master File for semaglutide API manufactured under a new process. FDA acknowledgment letter for JYMed’s Type II DMF filing for semaglutide API...
Rare Disease Day
A condition may be “rare,” but no person should feel invisible.At JY MedTech, we recognize the resilience of the rare disease community and the importance of continued collaboration across science and healthcare.Today, we stand with patients, families, advocates, and...
Happy Lunar New Year 2026 🧧
From all of us at JYMed Peptide, we wish our customers, partners, and friends around the world a joyful Lunar New Year, filled with good health, happiness, and success. Thank you for your continued trust and collaboration. We look forward to supporting your projects...









